Dyadic Announces Publication of C1 Monoclonal Antibody in Nonhuman Primate Study in Nature Communications
JUPITER, Fla., March 26, 2024 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic” or the “Company”) (NASDAQ:DYAI), a global biotechnology company focused on building innovative microbial protein production platforms today announced the online publication of the manuscript “Filamentous fungus-produced human monoclonal antibody provides protection against SARS-CoV-2 in hamster and nonhuman primate models” in Nature Communications (“Springer-Nature”), an international journal publishing peer-reviewed research in all fields of science and technology.